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Basal cell nevus syndrome (BCNS), also known as Gorlin syn-
drome (OMIM #109400) is a well-described rare autosomal
dominant condition due to haploinsufﬁciency of PTCH1.
With the availability of comparative genomic hybridization
arrays, increasing numbers of individuals with microdeletions
involving this locus are being identiﬁed. We present 10 previ-
ously unreported individuals with 9q22.3 deletions that include
PTCH1. While 7 of the 10 patients (7 females, 3 males) did not
meet strict clinical criteria for BCNS at the time of molecular
diagnosis, almost all of the patients were too young to exhibit
many of the diagnostic features. A number of the patients
exhibited metopic craniosynostosis, severe obstructive hydro-
cephalus, and macrosomia, which are not typically observed in
BCNS. All individuals older than a few months of age also had
developmental delays and/or intellectual disability. Only facial
features typical of BCNS, except in those with prominent mid-
foreheads secondary to metopic craniosynostosis, were shared
among the 10 patients. The deletions in these individuals ranged
from 352 kb to 20.5Mb in size, the largest spanning 9q21.33
through 9q31.2. There was signiﬁcant overlap of the deleted
segments among most of the patients. The smallest common
regions shared among the deletions were identiﬁed in order to
localize putative candidate genes that are potentially responsible
for eachof thenon-BCNS features. Thesewere a 929 kb region for
metopic craniosynostosis, a 1.08Mb region for obstructive
hydrocephalus, and a 1.84Mb region for macrosomia. Addi-
tional studies are needed to further characterize the candidate
genes within these regions.  2011 Wiley Periodicals, Inc.
Key words: PTCH1; 9q22; Gorlin syndrome; basal cell nevus
syndrome; basal cell carcinoma syndrome; metopic craniosynos-
tosis; chromosomal deletion
*Correspondence to:
LouanneHudgins, MD, Stanford University Division ofMedical Genetics,
300 Pasteur Drive, H315, Stanford, CA 94305-5208.
E-mail: lhudgins@stanford.edu
Published online 21 December 2011 in Wiley Online Library
(wileyonlinelibrary.com).
DOI 10.1002/ajmg.a.34216
How to Cite this Article:
Muller EA, Aradhya S, Atkin JF, Carmany EP,
Elliott AM, Chudley AE, Clark RD, Everman
DB,Garner S,Hall BD,HermanGE,Kivuva E,
Ramanathan S, Stevenson DA, Stockton DW,
Hudgins L. 2012. Microdeletion 9q22.3
syndrome includesmetopic craniosynostosis,
hydrocephalus, macrosomia, and
developmental delay.
Am J Med Genet Part A 158A:391–399.
 2011 Wiley Periodicals, Inc. 391
INTRODUCTION
Basal cell nevus syndrome (BCNS) is a well described cancer
predisposition and multiple malformation syndrome, manifested
by a constellation of ﬁndings that include lamellar calciﬁcation of
the falx cerebri at less than 20 years of age, palmar and/or plantar
pits, jawkeratocysts, basal cell carcinomas at less than30 years of age
(or more than four in a lifetime), cleft lip and/or cleft palate,
vertebral and rib anomalies, pre- or postaxial polydactyly, ocular
anomalies, occipitofrontal circumference of greater than 97th
centile, and an increased risk of childhood medulloblastomas
(primitive neuroectoderm tumor, PNET), lymphomesenteric or
pleural cysts, andovarianor cardiacﬁbromas [Kimonis et al., 2004].
Various dysmorphic facial features have beendescribed, including a
broad forehead with bossing, hypertelorism, epicanthal folds,
midfacial hypoplasia, short, high-set upturned nose, a long and
tented philtrum, and coarsened facies. This condition is known to
result from autosomal dominant loss of function mutations in the
PTCH1 gene and fromhaploinsufﬁciencyof thehumanhomolog to
the Drosophila patched protein [Hahn et al., 1996; Wicking et al.,
1997].While the average ageof clinical diagnosisofBCNS is25years
of age, with the increasing use of array-based comparative genomic
hybridization technology (CGH), individualswith contiguous gene
deletions that include PTCH1 are being identiﬁed at earlier ages,
often before manifestation of the characteristic age-dependent
BCNS features [Slater et al., 2000]. To date, 27 patients have
been reported with 9q22 deletions that either met clinical criteria
for diagnosis of BCNS, or include PTCH1 within the deleted
interval, excluding intragenic deletions [Sekhon et al., 1982; Ying
et al., 1982; Farrell et al., 1991; Robb et al., 1991; Evans et al., 1993;
Kroes et al., 1994; Shimkets et al., 1996; Paoloni-Giacobino et al.,
2000; L’Hermine et al., 2002;Olivieri et al., 2003;Haniffa et al., 2004;
Midro et al., 2004; Boonen et al., 2005; Cajaiba et al., 2006; Chen
et al., 2006; Redon et al., 2006; Fujii et al., 2007; Nowakowska et al.,
2007; de Ravel et al., 2009; Musani et al., 2009; Shimojima et al.,
2009; Yamamoto et al., 2009].
Recently, several authors have reported an emerging phenotype
separate from that ofBCNSresulting frommicrodeletions of 9q22.3
that include PTCH1 [Redon et al., 2006; Shimojima et al., 2009;
Yamamoto et al., 2009]. Macrosomia in these individuals has been
hypothesized to result from de novo deletions of the paternal allele
speciﬁcally, possibly due to the loss of one or more as-of-yet
unidentiﬁed imprinted genes, or possibly PTCH1 itself [Redon
et al., 2006; Yamamoto et al., 2009].
Here we report on 10 new patients with 9q22.3 deletions that
include PTCH1, of varying ethnic backgrounds and age at diag-
nosis, whose deletionswere analyzed by array CGHafter referral for
evaluation by a medical geneticist. We characterize new phenotypic
features not consistentwithBCNS (metopic craniosyntosis, obstruc-
tive hydrocephalus, macrosomia, and developmental delay), and
map the common areas of overlap among these deletions.
MATERIALS AND METHODS
Study Design
Patient 7 was ascertained by the lead and corresponding authors at
an outpatient referral for consultation by a medical geneticist. The
other authorswere then contacted directly for solicitationof similar
patients for inclusion in a retrospective case review series study,
after approval of the study and consent forms by the Stanford
Institutional Review Board (IRB). The other nine affected individ-
uals had been previously evaluated by one or more of the other
authors after referral from a medical geneticist evaluation. Clinical
andmolecular diagnosis of BCNSwas conﬁrmed by detection of an
interstitial 9q22.3 deletion that included PTCH1 by array-based
CGH, including BAC array, 44K oligonucleotide array, 105K
oligonucleotide array, and/or SNP array; some individuals had
more than one of these analyses. The only study inclusion criterion
was a conﬁrmed molecular diagnosis by one of the described
methods in a previously unreported individual.
Medical records regarding the affected individual’s phenotype,
including clinic notes by the authors, cytogenetic study reports, and
facial photographs if explicitly authorized, were sent by each
physician for compilation and review by the lead author. In
compiling the phenotypic features for each patient, macrosomia
was deﬁned as both height or length andweight of greater than 95th
centile.
Analysis
Each individual’s reported deletion breakpoints were put into the
UCSC Genome Browser (http://genome.ucsc.edu/) NCBI36/hg18
March 2006 build for analysis, in accordance to the human genome
assembly used in the cytogenetic report for each patient [Kent et al.,
2002]. The isolated regions were then converted to the current
GRCh37/hg19 February 2009 human genome assembly to obtain
the revised breakpoints, using tools available at the Genome
Browser site. The revised, current build breakpoints were then
input into the NCBI MapViewer website for gene annotation
using human genome build 37.2 (http://www.ncbi.nlm.nih.gov/
mapview/). Basepairs described in this report are for the NCBI36/
hg18 March 2006 build.
RESULTS
The 10 affected individuals included 7 females and 3 males, who
ranged in age at time of initial geneticist evaluation from newborn
to 7 years. Their ages at the time of conﬁrmed array-based molec-
ular diagnosis spanned from less than 1 month to 13 years.
Gestational ages at birth ranged from 37 to 41 weeks. Each of these
individuals was the only affected member in his or her family, and
the deletions were conﬁrmed as de novo in the nine for whom
parental samples were obtained. The ethnic background was Euro-
peanCaucasian (8), oneofwhomwasMennonite,Mexican (1), and
Chinese (1). These ﬁndings are summarized in Table I.
Using the previously proposed diagnostic criteria of two major
features, or one major plus two minor features, only three indi-
viduals (Patients 4, 5, and 6) met a clinical diagnosis of BCNS
[Evans et al., 1993; Slater et al., 2000]. Eachpersonexhibited someof
the characteristic features of BCNS, which included absolute mac-
rocephaly (6/10), rib and/or vertebral anomalies (5/8), ocular
malformations (3/10), numerous basal cell nevi (3/10),mandibular
odontogenic keratocysts (3/10), Sprengel deformity (3/10), cardiac
ﬁbromas (2/8), polydactyly (2/10), palmoplantar pits (2/10), and
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palatal clefting (2/10), among other features. Features not charac-
teristic of BCNS were metopic craniosynostosis, hydrocephalus,
macrosomia, and developmental delay with or without intellectual
disability. Trigonocephaly, resulting from metopic craniosynosto-
sis, was present in four individuals (Patients 1, 5, 7, and 8), each of
whom underwent corrective surgery. Obstructive hydrocephalus
was apparent in ﬁve individuals (Patients 2–5, 9), each of whom
required ventriculo-peritoneal shunting. One child, Patient 6, had
TABLE I. Summary of Patient Data
Features
Patient
1 2 3 4 5 6 7 8 9 10
Gender M F F M F F M F F F
Presenting age Birth 10 Days 2 Weeks 9 y Birth 9 mo 7 mo Birth 5 y 7 y
Race/Ethnicity Caucasian Caucasian Caucasian Mennonite Caucasian Chinese Mexican Caucasian Caucasian Caucasian
Diagnosis age 2 weeks 1 y 1 mo 9 y 13 y 2 y 2 y 2 mo 11 y 7 y
Last exam age 4 mo 5 y 9.5 mo 22 y 16 y 3 y 3 y 7 mo 13 mo N/A N/A
Deletion (Mb) 20.5 10.85 9.85 8.28 8.07 4.5 2.03 1.84 1.08 0.352
Metopic fusion þ    þ  þ þ  
Hydrocephalus  þ þ þ þ    þ 
Macrosomia      þ þ/ þ  
Delay ? Global Motora Global Global Global Global Motor Motor Motor
Intellect impaired ? þ ? þ þ ? ? ?  
Molecular array BAC BAC, 105K 105K SNP 105K BAC, 105K BAC, 105K 105K 105K, MLPA 44K
BCNS FEATURES
Craniofacial
Bossing  þ þ þ  þ þ   þ
Coarse face þ þ þ  þ     
Synophrys þ         
Epicanthal folds þ þ   þ þb þ þ  
Palpebral slanting  Down   Up Down   Down Up
Cleft Palate   Uvula      
Short nose þ þ  þ þ þ  þ  
Philtrum:
Long þ þ  þ þ   þ  
Tented þ þ   þ   þ  
Ears: low, angled þ  þ þ þ   þ þ þ
Abnormal dentition ?       þ þ 
Jaw keratocysts    þ þ    þ 
Macrocephaly  þ  þ þ þ þ þ  þ
Ocular anomalies   Nerve     Micro Retinal 
Skeletal
Rib anomaly þ ?  þ  þ þ ? þ 
Vertebral anomaly þ ?    þ  ? þ 
Sprengel deformity    þ  þ   þ 
Pectus deformity   þ þ      
(Kypho)scoliosis þ þ    þ   þ 
Polydactyly      þ  þ  
Syndactyly        þ  
Oligodactyly    þ þc     
Cardiac tumor RV    RA    ? ?
Dermatological
Basal cell Nevi    þ  þ þ   
Palmoplantar Pits      þ    þ
Neurological
Hypotonia þ þ þ  þ þ    
þ, present; , absent; ?, unknown or not assessed; 44K, 44K-oligonucleotide array; 105K, 105K-oligonucleotide array; BAC, bacterial artiﬁcial chromosome array; micro, microphthalmia and
optic nerve hypoplasia; MLPA, multiplex ligation-dependent probe ampliﬁcation; N/A, not applicable; nerve, optic nerve anomaly; retinal, abnormal retinal myelination; RA, right atrial; RV, right
ventricular; SNP, single nucleotide polymorphism array.
aNot assessed for speech or other delays.
bEpicanthal folds were present, but were also consistent with patient’s ethnicity.
cBilateral thumb hypoplasia was present.
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mild ventricular enlargement that didnot require shunting.Macro-
somia was present in two individuals (6, 8), each of whom also had
macrocephaly. One child (Patient 7) had a height between the 90th
and 95th centiles, and a weight at the 98th centile. As this did not
meet our strict deﬁnition ofmacrosomia, his deletionwas excluded
from the overlap region analysis for macrosomia. In all eight
individuals who were older than a few months of age and who
could be fully assessed, developmental delays were apparent. Only
motor delays were seen in the children with the smallest deletions,
which in some cases resolved over time. Global motor, speech/
language, and social/behavioral impairments were observed in
those with the larger deletions. Intellectual disability was apparent
in the three globally delayed patients who were followed to school
age and older. Hypotonia was present in half of the individuals
(Table I).
Various dysmorphic facial features were present in a number of
patients, and included a broad forehead with bossing, vertical
forehead creases, epicanthal folds, angulated palpebral ﬁssures,
micrognathia, and low-set and posteriorly rotated ears. Noted
among many of the patients were a short nose with the appearance
of being ‘‘high set,’’ and a long and tented philtrum (Table I; Fig. 1).
The facial features also coarsened over time in two individuals
(Patients 2, 8; Fig. 2).
Features present in some members of our population were
synophrys, hypertelorism, partial corpus callosum dysgenesis,
Chiari I malformation, seizures, joint hypermobility, camptodac-
tyly, ataxia, short stature, broad/webbed neck, and inguinal hernias
(data not shown). One child (6) had unilateral renal cysts, mild
ipsilateral ureterectasis that resolved spontaneously, and contrala-
teral mild renal pelviectasis. None of the other nine individuals had
any documented renal anomalies.
All of our reported individuals except Patient 9 had G-banded
chromosomal analysis. The deletions of Patients 1, 3, and 4 were
visible onhigh-resolutionanalysis. Theothershad lower-resolution
chromosomal analysis, and their deletions were not visible micro-
scopically (data not shown). Overall, the deletion sizes ranged from
352 kb, containing only PTCH1 and part of FANCC, to 20.5Mb,
spanning 273 genes, as illustrated (Fig. 3). Individual 3 also had a
second 44Kb deletion located at 9q21.3, which contained no genes
(data not shown). The smallest region of deletion overlap for the
ﬁve affected individuals with metopic craniosynostosis was 929 kb,
between bases 96,771,450 and 97,700,488, and which contained
FIG. 1. Five individuals with interstitial 9q22.3 deletions. Please note the short nose and long philtrum that is best observed in patients 1, 3, and 8, but
is alsopresent in patient 4, and the lowset andposteriorly rotated ears inall of the patients. Tenting of the philtrum is alsopresent inpatients 1and8.
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FIG. 2. Age progression in individuals with interstitial 9q22.3 deletions. A. Patient 2 at age 6 months and 19 months (top row, left-to-right), and at
34 months, 4 years, and 5 years (bottom row, left-to-right). Age progression in individuals with interstitial 9q22.3 deletions. B. Patient 5 at age
5 months (top and middle rows), 11 years (bottom left), and 16 years (bottom right). Again note the short nose and long, tented philtrum in both
patients.
FIG. 3. Schematic representation of thedeletions inaffected individuals. Thedeletions for eachaffected individual, listed on the left, are represented to
scale by horizontal bars of various colors, in comparison to a chromosome 9q ideogram along the top. Bars composed of two colors indicate the
presence of both features. The relative position and size of PTCH1 is represented by a vertical bar. Listed deletion breakpoints are according to the
NCBI 36/hg18 build.
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15 annotated genes other thanPTCH1. Therewas a commonarea of
deletionoverlapof 1.08Mbamongpatientswithobstructivehydro-
cephalus that contained 17 genes other than PTCH1. This region
localized to bases 96,848,332 through 97,930,074. The smallest
region of deletion overlap for the two patients with macrosomia
was 1.8Mb, located between bases 96,771,450 and 98,619,830. This
region contained 30 genes other than PTCH1.
DISCUSSION
We have expanded the phenotype of individuals with interstitial
9q22 deletions that contain PTCH1 to include metopic craniosy-
nostosis, obstructive hydrocephalus, and macrosomia, which are
separate from the typical features of BCNS. This would suggest that
there are genes other than PTCH1 in the deleted region that when
deleted contribute to these conditions.
The common area of overlap among the patients with metopic
craniosynostosis, resulting in trigonocephaly, was between base-
pairs 96,771,450 and 97,700,488. There are 15 genes other than
PTCH1 within this region. These are FANCC, encoding the
Fanconi anemia complementation group C protein, open reading
frames that encode a zinc aminopeptidase (c9orf3), a putative
repair/recombination helicase (c9orf102), and a nasopharyngeal
carcinoma-associated protein (c9orf130), four pseudogenes, two
hypothetical RNA-encoding genes (LOC100507319, LOC100507346),
one gene that is expressed in human heart and brain and encodes a
hypothetical protein of unknown function (LOC100506667), and
four microRNA genes. While there are no obvious candidate genes
among those listed, it is possible that the deleted regionmay include
one gene whose haploinsufﬁciency is but one of many factors that
inﬂuence the development of metopic craniosynostosis in affected
individuals, perhaps explaining why every individual who shared
our mapped minimal region for metopic craniosynostosis did not
demonstrate that ﬁnding. The presence of metopic craniosynos-
tosis in a substantial percentage of all reported individuals with
9q22.3 microdeletion is interesting. We do suggest that 9q22.3
microdeletion be included in the differential diagnosis for individ-
uals with metopic craniosynostosis in the absence of multiply
affected sutures, and as such, CGH studies may be indicated.
In comparison, the commonly deleted region among individuals
with obstructive hydrocephalus was located between 96,848,332
and 97,930,074. Within this region were the same three open
reading frames, four microRNA genes, FANCC, hypothetical pro-
tein gene, and one of the two hypothetical non-protein encoding
RNA genes which were also present in the deletions of individuals
with metopic craniosynostosis. Unique to this region was another
pseudogene, a non-protein coding RNA gene, and an additional
hypothetical RNA-encoding gene. Again, there are no obvious
candidate genes among them.
We note that asymmetric ventricles, dilated ventricles, and
dilation due to cerebral atrophy have been reported in the literature
on patients with the clinical diagnosis of BCNS [Chen et al., 2006].
We cannot determine whether all of these individuals have inter-
stitial deletions that contain PTCH1, as the diagnosis of BCNS was
purely clinical before the genetic etiology was identiﬁed [Hahn
et al., 1996]. Similarly, some of the 27 previously described indi-
viduals with known interstitial 9q22 deletions that contain PTCH1
by mapping or by BCNS diagnosis have had ventricular dilation of
varying degrees [Robb et al., 1991; Kroes et al., 1994; Midro et al.,
2004; Boonen et al., 2005; Cajaiba et al., 2006; Chen et al., 2006;
Redon et al., 2006; Fujii et al., 2007], or like many of our newly
reported patients, hydrocephalus requiring ventriculo-peritoneal
shunting [Farrell et al., 1991; Shimkets et al., 1996]. Without the
higher resolution mapping available with current technology, we
cannot reﬁne the critical regions for those patients beyond those
large regions achieved by linkage analysis or BAC array-based
methods utilized in those studies. We do expect the critical region
to overlap with our proposed minimal intervals, however, due to
the large size of the reported deletions in the older case reports. In
two of the most recently described patients, mild dilation of one or
more ventricles was present, and linked to the presence of a space-
occupying lesion [Shimojima et al., 2009; Yamamoto et al., 2009].
Wedonot consider this to be obstructive hydrocephalus of a nature
similar to that in our described patients who required shunting,
though one of our patients (6) did have mild enlargement of the
ventricle and cerebral sulci (Table II). Overall, a higher proportion
of our newly reported individuals had more severe forms of
ventricular dilation requiring intervention than those reported
previously, whereas the earlier reports described a higher frequency
of less severe forms. This may be the result of the more severely
affected individuals being brought to medical attention at younger
ages in response to rapidly increasing head size, and/or seizures,
prompting additional evaluations for other abnormal phenotypic
features, and thus allowing diagnosis of 9q22.3 microdeletion
earlier than would otherwise be expected. Alternatively, milder
forms may only be ascertained incidentally as part of a brain
imaging evaluation for developmental delay or as part of the
neuroimaging for BCNS, may be generally underreported, or
may be missed altogether because such imaging is sometimes
difﬁcult in developmentally delayed or impaired children who
are behaviorally noncompliant during the study. We suggest that
brain imaging be performed as part of the initial evaluation for
9q22.3microdeletion, and surveillancemonitoring of head circum-
ference be performed at all clinical visits (Table III).
We described two individuals with macrosomia, as pre-deﬁned
by height or length and weight each at the 95th centile or greater.
The deletions of these children contained the common region of
basepairs 96,771,450 through 98,619,830. In addition to the pre-
vious 18 genes (other than PTCH1) described for the regions
common among affected individuals with metopic craniosynos-
tosis and among thosewith hydrocephalus, there were 12 genes that
were unique to this region. These included three pseudogenes, a
hypothetical RNA-encoding gene, and an open reading frame
(c9orf21) that encodes a protein with peroxiredoxin-like domains.
Also among the genes unique to this common deletion were the
genesHSD17B3, which encodes a 17-hydroxy-steroid dehydrogen-
ase; SLC35D2, which encodes an endoplasmic reticulum/Golgi
apparatus nucleotide sugar transporter; and, HABP4, encoding
an intracellular hyaluronan binding protein. Perhaps most inter-
estingly, also located within the region are CDC14B, encoding the
human homolog of a yeast cell division cycle protein, and ZNF510
and ZNF782, which encode novel zinc ﬁnger-containing proteins
that have been implicated in association studies with regard to
modulation of stature speciﬁcally within the Chinese population
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[Lei et al., 2009]. Of note, one of our two reported individuals with
macrosomia was Chinese.
Previous case reports have focused on correlating overgrowth in
individuals with 9q22.3 deletions that include PTCH1 with loss of
the paternal allele [Redon et al., 2006; Shimojima et al., 2009]. The
inference is that loss of one or more imprinted genes within the
region, perhaps even PTCH1, is a cause of macrosomia. In our
review of the 27 previously reported affected individuals, six had
macrosomia [Cajaiba et al., 2006; Chen et al., 2006; Redon et al.,
2006; Shimojima et al., 2009; Yamamoto et al., 2009]. Notably, this
number differs from those reviewed and reported by Shimojima
et al., as we included an individual with hemihyperplasia, and we
excluded the thirdpatient of Farrell et al. [Farrell et al., 1991;Cajaiba
et al., 2006]. This latter child had a birth length and weight of 90th
and 97th centiles, respectively, and her length had decreased to 75th
centile by 7months of age. Of the six individuals withmacrosomia,
TABLE III. Suggested Evaluations After a Diagnosis of 9q22.3 Microdeletion
Clinical concern Evaluation strategy
Hydrocephalus, ventricular dilation Brain imaging
Complete neurological evaluation
Cerebral tumorsa Surveillance monitoring of head circumference
Macrosomia, hemihyperplasia Surveillance monitoring of growth parameters
Metopic craniosynostosis Complete craniofacial assessment
Carefully consider cost versus beneﬁt of radiographic imaging
Developmental delay Microarray/CGH of high resolution to conﬁrm extent of deletion
Formal developmental assessment
Intellectual impairment Childhood intervention services referrals
Renal anomalies Renal ultrasound
Ovarian ﬁbromaa Abdominal/pelvic ultrasound
Basal cell carcinomaa Periodic complete dermatological assessment
Avoidance of ionizing and UV radiation exposure
Cardiac anomalies, ﬁbromaa Echocardiogram
Ocular anomaliesa Ophthalmological evaluation.
Skeletal anomaliesa Carefully consider cost versus beneﬁt of radiographic imaging
Odontogenic keratocystsa
CGH, comparative genomic hybridization.
aIndicates a feature of BCNS.
TABLE II. Comparison of Patients With Interstitial 9q22.3 Deletions
Non-BCNS features
Affected individuals
This study Previous studies Total cumulative
Number Percent (%) Number Percent (%) Number Percent (%)
Metopic craniosynostosis 4/10 40 4/27 14.8 8/37 21.6
Ventricular dilationa
Hydrocephalus 5/10 50 2/27 7.4 7/37 18.9
Mild dilation 1/10 10 8/25b 32 9/35 25.7
Macrosomiac 2/10 20 6/27 22 8/37 21.6
Developmental delay
Motor only 3/8d 37.5 7/22e 31.8 10/30 33.3
Speech only 0/8 0 0/22 0 0/30 0
Global 5/8 62.5 14/23e 60.8 19/31 61.3
Intellectual disability 3/5 60 14/23e 60.8 17/28 60.7
aHydrocephalus refers to severe and obstructive ventricular dilation that required ventriculo-peritoneal shunting, whereas mild dilation did not, and may have been asymmetric,
or of only one ventricle.
bExcludes one case caused by cerebral atrophy and two cases caused by space-occupying masses.
cDeﬁned as both height (length) and weight >95 percentile.
dExcludes patients with motor delay, but who were not old enough to assess speech and for other impairments.
eExcludes patients without clear description of delays and/or impairment.
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ﬁve had lost the paternal allele, though Yamamoto et al. did not
report the parent of origin for their patient’s allele [Farrell et al.,
1991; Cajaiba et al., 2006; Chen et al., 2006; Redon et al., 2006;
Shimojima et al., 2009; Yamamoto et al., 2009]. Three other
individualswith loss of thepaternal allele hadnormal orunreported
growth parameters [Shimkets et al., 1996; Olivieri et al., 2003; Fujii
et al., 2007]. In contrast, of the four people whowere known to have
lost thematernal allele, one was reported as having normal growth,
one was reported as having small stature, and the other two did not
have reported growth descriptions [Ying et al., 1982; Shimkets et al.,
1996; Midro et al., 2004; Fujii et al., 2007; Shimojima et al., 2009;
Yamamoto et al., 2009]. We did not determine the parental origin
for the deleted allele in our reported individuals, as these studies
were not originally performed for any of the individuals on whom
parental samples were available, and were outside of the scope
permitted by our institutional IRB-approved protocol and consent
for this retrospective study. In all of the previously reported
individuals with macrosomia for whom we could identify the
breakpoints from the published report, each shared the smallest
commonly deleted region identiﬁed in our two children with
macrosomia, though again, comparison with the earlier studies
before the use of array CGH technology is difﬁcult [Chen et al.,
2006; Redon et al., 2006; Shimojima et al., 2009]. Based on all of the
reported patients to date, there is no consistent evidence for
imprinted genes located around or including PTCH1, as there
do not seem to be two distinct (opposite) phenotypes, each
segregating with loss of a particular parental allele, especially
with respect to growth. While we cannot deﬁnitively exclude the
possibility of candidate genes within the commonly deleted inter-
val, or their downstream effectors, being imprinted at this time,
there is no uniparental disomy 9 phenotype described the in the
medical literature [Wilkinson et al., 1996; Slater et al., 2000].We do
feel that additional study with regard to parent of origin for the
deleted alleles is warranted, and also suggest consideration of SNP
or array CGH as part of the evaluation of individuals with macro-
somia or generalized overgrowth. There is no evidence at this time
to determinewhether routine surveillance for abdominal tumors in
individuals with 9q22.3 microdeletion and macrosomia or hemi-
hyperplasia is warranted. It is expected that individuals with 9q22.3
microdeletion have the same or similar risk for tumor types that are
seen with increased frequency in individuals with BCNS, though
there is limited information available, given how few affected
individuals have been reported to date.
In all eight of our affected individuals who were of sufﬁcient age
and could be adequately assessed, developmental delays and/or
intellectual disabilitywas present. The smallest deletion, containing
onlyPTCH1 and a portion of FANCC, was present in individual 10,
who exhibitedmotormilestone delays. It is likely that her delays are
related to PTCH1 haploinsufﬁciency alone. In our reported indi-
viduals with deletions of approximately 2Mb and larger, global
impairment, including impairment of speech and language, and in
the older individuals, intellectual disability, were present in addi-
tion to motor developmental delay. This phenomenon is not
unique to the speciﬁc genes within the deleted intervals, as numer-
ous contiguous gene deletion syndromes showmore severe impair-
mentwith increasing deletion sizes [Slavotinek, 2008;Musani et al.,
2009]. Our most severely affected person overall, with an approx-
imate 20.5Mb deletion, was too young to be fully assessed, but was
noted to have hypotonia and failure to thrive, and died in infancy of
complicationsof a respiratory illness.Hadhe lived, it is likely that he
would have had signiﬁcant developmental and intellectual disabil-
ities in the future.
The majority of our reported individuals were female. While
equal numbers of affectedmales and females are expected, based on
the autosomal nature of the chromosome deletion, we cannot
explain this ﬁnding by any systemic ascertainment bias. Of the
27previously describedpeoplewith9q22deletions that causeBCNS
or include PTCH1, there were 14 males, 12 females, and 1 sex
unreported, showing no sex-related skewing.
Overall, as summarized in Table II, 40% of our population
demonstrated metopic craniosynostosis, compared to approxi-
mately 15% of the previously reported 27 individuals with inter-
stitial 9q22 deletions. In our reported affected individuals, half had
obstructive hydrocephalus, compared to approximately 7% of
those who have been previously reported. In contrast, almost a
third of the previously reported individuals presented with milder
forms,whereas only one child (10%) in our study did. Similar to the
previous reports, 20% of our population demonstrated macro-
somia of greater than 95th centile for height (or length) and for
weight. Developmental delay and/or irreversible intellectual
impairment was present to a similar degree both in our affected
individuals, and in those in the previous case reports, though direct
comparison is difﬁcult because of limited data and the widely
variable ages of all of the patients.
It is unclear as to the mechanism which predisposes the 9q22.3
region to deletion. In silico analysis using the RepMask 3.27 tool
available on theUCSCGenomeBrowser (http://genome.ucsc.edu/)
identiﬁednumerous SINEs, largeLINEs, andLTRsﬂankingPTCH1
and adjacent genes in the region, which potentially could result in
recombinatory deletion and duplication events. Perhaps reﬂective
of a reciprocal recombination event to the 9q22.3 microdeletion, a
mother and child with the shared phenotype of microcephaly and
mild developmental delay was each reported to have a 360 kb
duplication of the 9q22.3 region that included PTCH1 and exon
1 of FANCC [Derwinska et al., 2009].
In summary,wedescribe10additional individualswithdeletions
involving 9q22 that include the PTCH1 gene. The ﬁndings in these
10 people broaden the phenotype to include metopic craniosynos-
tosis, hydrocephalus, macrosomia, and developmental delay with
intellectual disability.Whilemanyof the affected individuals shared
similar dysmorphic features that have been previously described
in patients with BCNS, no other unifying characteristic facial
phenotype was recognized, except with respect to that resulting
from metopic craniosynostosis. These ﬁndings have implications
for clinical care in individuals with 9q22.3 microdeletion
(summarized in Table III), as well as for identifying genes that
contribute to the expanded phenotype. Further studies are neces-
sary to further reﬁne the smallest areas ofoverlap inorder to identify
the genes implicated in these ﬁndings.
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